Bristol-Myers Squibb (BMY) Reports In-Line Q2 EPS, Updates FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bristol-Myers Squibb Reports Second Quarter Financial Results
July 27, 2017 6:59 AM EDTIncreases Second Quarter Revenues 6% to $5.1 Billion Posts Second Quarter GAAP EPS of $0.56 and Non-GAAP EPS of $0.74 Achieves Important Clinical and Regulatory Milestones in Immuno-Oncology Opdivo Approved in Europe for Advanced Form of Bladder Cancer and Squamous Cell Carcinoma of the Head and Neck Opdivo Application for Previously Treated Hepatocellular Carcinoma Granted Priority Review in the U.S. Yervoy Approved in the U.S. for Pediatric Patients with Metastatic Melanoma... More
